For decades, ovarian cancer treatment followed a familiar cycle: chemotherapy, remission, recurrence. For patients with platinum-resistant epithelial ovarian cancer, that can quickly become a frustrating cycle. Standard options narrow, responses shorten, and the search for something better becomes urgent.
That urgency now has a credible answer.
Folate Receptor-alpha (FR-α) is overexpressed in approximately 70% to 90% of epithelial ovarian cancers, making it one of oncology’s most compelling targets.
Folate receptor alpha ovarian cancer treatments represent a fundamentally different approach that exploits a biological marker found on most ovarian tumors. Testing for FR-α is no longer optional; it’s the gateway to the most promising breakthroughs available today.
To understand it matters, you first need to know what FR-α actually does inside a tumor cell.
Understanding the biology: What is folate receptor alpha?
Folate receptor alpha (FR-alpha) is a protein that sits on the surface of certain cells and acts like a docking station, grabbing folate (vitamin B9) from the bloodstream to fuel cell growth. Normal cells have relatively few of these receptors. But many ovarian cancer cells are covered in them, a biological quirk that makes FR-alpha an ideal target for precision medicine.
Not every patient qualifies. According to the National Institutes of Health, approximately 70% to 80% of patients with advanced high-grade serous ovarian cancer have high FR-alpha expression. This means at least 75% of their tumor cells test positive at a meaningful intensity. That threshold matters enormously when it comes to treatment eligibility.
Evidence-based guidance powered by NCCN Guidelines®
Personalized treatment plans shaped by the latest oncology standards—tailored to your diagnosis.
Get started
View your personalized treatment plan in the Outcomes4Me app
Use your diagnosis to unlock personalized NCCN Guidelines®-aligned recommendations.
Continue in app
Key definition: Immunohistochemistry (IHC) is a lab technique that uses antibodies to detect specific proteins (like FR-alpha) on tumor tissue. The good news: this test can often be run on tissue already collected during a prior biopsy or surgery, so no additional procedure is typically required. Results are scored by the percentage of cells that stain positive and how intensely they react.
Knowing your FR-alpha status is now a meaningful clinical data point that determines whether a new class of treatments could work for you. That leads directly to the most important drug in this space right now.
The current gold standard: Mirvetuximab soravtansine (Elahere)
In 2024, the FDA granted full approval to mirvetuximab soravtansine-gynx (Elahere), marking a genuine turning point for patients with FR-alpha-positive, platinum-resistant epithelial ovarian cancer.
How mirvetuximab soravtansine works
Mirvetuximab soravtansine is an antibody-drug conjugate (ADC). The antibody component locks onto FR-alpha proteins overexpressed on tumor cells, delivers a potent chemotherapy payload directly inside, then releases it to destroy the cell from within. Healthy cells with little to no FR-alpha expression are largely spared. It’s targeted destruction, not a broad chemical sweep.
What the MIRASOL trial proved
The pivotal MIRASOL trial demonstrated that mirvetuximab soravtansine significantly improved both progression-free survival and overall survival compared to standard chemotherapy, a benchmark that had eluded this patient population for years.
Who is eligible?
Patients most likely to benefit share these characteristics:
- FR-alpha-positive tumor status (confirmed by diagnostic testing)
- Platinum-resistant epithelial ovarian cancer
- Prior treatment with one to three lines of therapy
This is why matching genetic results to ovarian cancer clinical trials and approved therapies matters so much because eligibility hinges on biomarker confirmation.
Emerging therapies: What’s coming in 2026
A new wave of FR-alpha targeted drugs is advancing quickly — and some are designed specifically for patients who’ve already exhausted prior options.
Drug Name | Status | Key Benefit |
Mirvetuximab soravtansine (Elahere) | FDA approved (2024) | High FR-alpha expression, platinum-resistant |
Sofituzumab vedotin (LY4170156) | Breakthrough Therapy designation (Jan 2026) | Active even after mirvetuximab progression |
Rintodestrant | Phase II trials | Effective in heavily pretreated patients |
The most significant recent development is sofetabart mipitecan. In January 2026, the FDA granted it Breakthrough Therapy designation, recognizing its activity even in patients who previously progressed on mirvetuximab soravtansine. That’s a meaningful shift and suggests the FR-alpha pathway can be targeted more than once with different mechanisms.
Equally important is the push toward treating patients with low FR-alpha expression, a group historically excluded from targeted therapy. If low-expression patients can benefit, FR-alpha targeting becomes relevant to nearly everyone with epithelial ovarian cancer. Understanding how to find clinical trials for FR-alpha ovarian cancer is increasingly critical, since many of these next-generation options are only accessible through active trials, a process we’ll walk through in the next section.
How to match your genetic results to clinical trials
Knowing that FR-alpha targeted therapies exist is one thing, but accessing them is another. With emerging ovarian cancer therapies moving fast, here’s a clear action plan to help you turn biomarker knowledge into real treatment options.
- Request the FR-alpha IHC test. Ask your oncologist specifically for a folate receptor alpha immunohistochemistry (IHC) test on your tumor tissue. This single test determines your eligibility for mirvetuximab soravtansin and a growing list of investigational therapies.
- Use a biomarker-matching platform. Myriad Genetics recently added Folate Receptor Alpha to its Precise Oncology Solutions to help connect patients to targeted therapies — making it easier than ever to translate results into next steps.
- Search ClinicalTrials.gov strategically. Use keywords like “folate receptor” or “FR-alpha” to filter relevant studies. Actively recruiting trials are adding FR-alpha positive patients right now.
Taking control of your treatment path
FR-alpha is a must-test biomarker for anyone with epithelial ovarian cancer. The approval of mirvetuximab soravtansine proved that targeting FR-alpha can meaningfully extend lives, and the next generation of therapies is already close behind.
You don’t have to navigate this alone or passively. Seek a second opinion at an academic medical center, where FR-alpha trials are most active and specialists stay current with fast-moving research.
Your next steps:
- Ask your provider for FR-alpha testing at diagnosis or recurrence
- Request a tumor biomarker report you can bring to any specialist
- Connect with a trial-matching platform to find open studies
- Visit an academic cancer center for a second opinion
- Download a Doctor Discussion Guide to prepare your questions
The patients who benefit most from breakthrough therapies are the ones who ask for testing before they need it. Start that conversation today. And join the Outcomes4Me ovarian cancer Community to connect with other patients undergoing your same experience.
Personalized support for real care decisions
Understand your diagnosis, explore clinical trials, and track symptoms--all in one place.
Get started
Compare treatments, prepare for appointments, and track side effects—all in the app
Built for your diagnosis, Outcomes4Me gives you the tools to make confident, informed decisions—right when you need them.
Continue in app
